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Case report 
Efficacy of glutathione therapy in relieving dyspnea associated with 
COVID-19 pneumonia: A report of 2 cases 
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Purpose: Infection with COVID-19 potentially can result in severe outcomes and death from “cytokine storm 
syndrome”, resulting in novel coronavirus pneumonia (NCP) with severe dyspnea, acute respiratory distress 
syndrome (ARDS), fulminant myocarditis and multiorgan dysfunction with or without disseminated intravas-
cular coagulation. No published treatment to date has been shown to adequately control the inflammation and 
respiratory symptoms associated with COVID-19, apart from oxygen therapy and assisted ventilation. We 
evaluated the effects of using high dose oral and/or IV glutathione in the treatment of 2 patients with dyspnea 
secondary to COVID-19 pneumonia. 
Methods: Two patients living in New York City (NYC) with a history of Lyme and tick-borne co-infections 
experienced a cough and dyspnea and demonstrated radiological findings consistent with novel coronavirus 
pneumonia (NCP). A trial of 2 g of PO or IV glutathione was used in both patients and improved their dyspnea 
within 1 h of use. Repeated use of both 2000 mg of PO and IV glutathione was effective in further relieving 
respiratory symptoms. 
Conclusion: Oral and IV glutathione, glutathione precursors (N-acetyl-cysteine) and alpha lipoic acid may 
represent a novel treatment approach for blocking NF-κB and addressing “cytokine storm syndrome” and res-
piratory distress in patients with COVID-19 pneumonia.   
1. Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first 
identified in Wuhan, China is responsible for the coronavirus disease 
outbreak of 2019 (COVID-19), now declared a pandemic by the World 
Health Organization (WHO) as of March of 2020 [1]. Among the CoV’s 
known to cause human disease, the three most highly pathogenic of the 
group include the SARS coronavirus (SARS-CoV now named 
SARS-CoV-1) [2], the Middle East respiratory syndrome (MERS) coro-
navirus (MERS-CoV) [3] and SARS-CoV-2, the agent of COVID-19, 
identified in patients with severe pneumonia in Wuhan, China [4]. 
Early prodromal symptoms of infection with COVID-19 include 
anosmia, hyposmia and dysgeusia [5] followed days later by fever 
(91.7%), cough (75.0%) and shortness of breath, fatigue (75.0%) and 
gastrointestinal symptoms including diarrhea (39.6%) [6]. A sore 
throat, headache, myalgias and rarely conjunctivitis has also been re-
ported [7] as well as episodes of confusion [8]. This is similar to the 
clinical picture of MERS, where a fever, chills, cough, sore throat, 
wheezing, shortness of breath, myalgia, chest pain, gastro-intestinal 
symptoms (diarrhea, vomiting, and abdominal pain) and confusion may 
result [9]. 
Although exposure to COVID-19 is asymptomatic or mild in most 
affected of younger age, those at highest risk for fulminant disease have 
been identified as having certain risk factors. These factors include 
advanced age and a smoking history [10], male gender [11], race 
(African-American) [12], as well as prior medical problems including 
hypertension, cardiac disease, obesity, hemorrhagic or ischemic stroke, 
underlying respiratory illness (asthma, emphysema), cancer, immuno-
suppression, secondary infections as well as chronic kidney and liver 
disease [13–15]. More than 100,000 people have died worldwide in the 
COVID-19 pandemic as of April 10, 2020 according to recent data from 
Johns Hopkins University [16]. As of April 11, 2020, almost 1.7 million 
people worldwide have been infected [17] with global mortality rates 
over time leveling off to a higher rate of 5.7% converging with current 
WHO estimates [18]. These statistics reveal that we may have 
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underestimated the potential threat of COVID-19, and that rapid, 
effective testing strategies and treatments are essential, especially 
among those with severe respiratory complications and acute respira-
tory distress syndrome (ARDS). 
Among the sickest patients and most common reasons for admission 
to the intensive care unit (ICU) during the initial outbreak of COVID-19 
in the Seattle area were hypoxemic respiratory failure leading to me-
chanical ventilation, hypotension requiring vasopressor treatment, or 
both [19]. Mortality among these critically ill patients was high. The ICU 
mortality rate among those who required non-invasive ventilation in 
one case series in China was 79% and among those who required 
invasive mechanical ventilation was 86% [15]. The fundamental path-
ophysiology of infection with COVID-19 potentially resulting in such 
critical outcomes is “cytokine storm syndrome” with ARDS and fulmi-
nate myocarditis [20] with multiorgan dysfunction [7] acute kidney 
injury, liver dysfunction, and pneumothorax [21]. A hyperinflammatory 
syndrome known as secondary hemophagocytic lymphohistiocytosis 
(sHLH) or macrophage activation syndrome (MAS) can also result from 
fulminant and fatal hypercytokinemia [22]. Pulmonary involvement in 
patients with HLH/MAS revealed that dyspnea and cough were the most 
common symptoms at the onset of the disease, and radiographs revealed 
interstitial infiltrates with centrilobular nodules, ill-defined consolida-
tion, or localized ground-glass opacities [23]. Similar radiological ab-
normalities are seen in patients who recovered from COVID-19 
pneumonia, where initial lung findings on chest CT revealed small 
subpleural ground glass opacities (GGO) that grew larger with 
crazy-paving pattern and consolidation up to two weeks after disease 
onset, eventually being absorbed resulting in extensive GGO and sub-
pleural parenchymal bands [24]. Chest radiographs and imaging results 
of patients with MERS Cov also have also shown features that resemble 
the findings of organizing pneumonia, which are different however from 
SARS, which show more of a fibrocellular intra-alveolar organization 
with a bronchiolitis obliterans organizing pneumonia-like pattern [9]. 
Despite differences in initial presentation, ARDS has been reported to 
be the main cause of death in COVID-19 15, resulting from an uncon-
trolled systemic inflammatory response releasing large amounts of pro- 
inflammatory cytokines as well as chemokines by immune effector cells 
[25]. This is similar to the pathophysiology seen with SARS, i.e., im-
mune cell injury–based damage with widespread organ involvement 
[26], with unbalanced cytokine and chemokine profiles [27,28]. 
Addressing the immune based lung pathology seen in COVID-19, similar 
to that seen in ARDS, might help to decrease morbidity and mortality. 
ARDS is caused by lung inflammation and increased alveolar endo-
thelial and epithelial permeabilities [29] leading to a protein-rich pul-
monary edema that causes severe hypoxemia and impaired carbon 
dioxide excretion [30]. The lung injury is non-cardiogenic in nature and 
caused primarily by neutrophil-dependent and platelet-dependent 
damage to the endothelial and epithelial barriers of the lung, 
frequently caused by pneumonia [30]. A procoagulant effect with 
coagulopathy and anti-phospholipid antibodies has also recently been 
reported in patients with COVID-19 [31], associated with a poorer 
prognosis in patients with novel coronavirus pneumonia (NCP) [32]. 
Supportive measures in the management of ARDS have included atten-
tion to fluid balance, restrictive transfusion strategies, and minimization 
of sedatives and neuromuscular blocking agents, along with inhaled 
bronchodilators which have been shown to confer short term improve-
ment without proven effect on survival [33]. 
Release of pro-inflammatory cytokines, such as Tumor Necrosis 
Factor alpha (TNF-α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and 
interleukin 8 (IL-8) which in turn recruit components of the innate im-
mune system have been shown to be associated with ARDS [34,35]. 
Neutrophils are recruited to the lungs by these cytokines, which then 
become activated and release toxic mediators [36], leading to extensive 
free radical production and reactive oxygen species which overwhelms 
endogenous anti-oxidants resulting in oxidative cell damage to lung 
tissue [37]. Pharmacological therapies that have been tried to date 
include nitric oxide, inhaled prostacycline, vasoconstrictors and 
anti-inflammatory agents including corticosteroids. Corticosteroids, 
however, have been shown to have no benefit and even cause harm [33]. 
Activation of nuclear factor-kappaB (NF-kappaB) has been shown to 
be required for transcription of the genes for many of the pro- 
inflammatory mediators associated with ARDS [38] where NF-κB 
plays a key role in the orchestration of the multifaceted inflammatory 
response. This is both in the pro-inflammatory phase and later in the 
regulation of the resolution of inflammation when anti-inflammatory 
genes are expressed [39]. Antioxidant therapies including N-ace-
tyl-cysteine (NAC) [40], alpha lipoic acid (ALA) [41,42] and glutathione 
(GSH) have all been reported to regulate NF-κB signaling [43] and 
downregulate NF-kappaB [44]. To date there are no clinical trials using 
either precursors of glutathione (NAC) or PO/IV glutathione for 
COVID-19 dyspnea, pneumonia or ARDS. 
Prior published, controlled clinical trials with NAC demonstrated 
that patients with ARDS have depressed plasma and red cell glutathione 
concentrations. These levels are substantially increased by therapy with 
intravenous NAC with measurable clinical responses to treatment 
regarding increased oxygen delivery, improved lung compliance and 
resolution of pulmonary edema [45]. The alveolar epithelial lining fluid 
of patients with ARDS has also been shown to be deficient in total GSH 
compared to normal subjects, where reactive oxygen species may play a 
key role in the pathogenesis of the acute lung injury with ARDS [46]. 
Since patients with ARDS are subjected to an increased burden of oxi-
dants in the alveolar fluid, principally released by recruited neutrophils, 
this deficiency of GSH may predispose these patients to enhanced lung 
cell injury. Glutathione is one of the body’s master antioxidants which 
has been shown to play an important role in antioxidant defense, 
nutrient metabolism, and regulation of cellular events, including cyto-
kine production and immune response [47]. We therefore performed a 
trial of glutathione precursors, i.e. NAC, antioxidants (alpha lipoic acid, 
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Vitamin C) along with 2-g doses of PO and/or IV glutathione in 2 pa-
tients suffering from dyspnea associated with COVID-19 pneumonia 
who were previously on antibiotic treatment for COVID-19 pneumonia 
with mixed results. 
2. Material and methods 
A screening questionnaire for COVID-19 was used to track daily 
symptoms. The initial COVID-19 screening questionnaire and follow-up 
form included the following symptoms that were tracked during the 
course of illness: loss of sense of smell and/or taste; sore throat; fever, 
sweats, chills; cough (and whether it was dry or productive with asso-
ciated shortness of breath); pulse oximetry readings if available, 
measured both without and with oxygen via nasal cannula; diarrhea; 
nasal congestion, sneezing, rhinorrhea; conjunctivitis; headaches; my-
algias and/or arthralgias; and memory or concentration problems. 
2.1. Participants 
A 54-year-old white male and 48-year-old white female contacted 
our office after testing positive for COVID-19 by either antibody testing 
(patient 1) or with radiology exams (chest x-ray, CT scan) consistent 
with COVID-19 pneumonia (patients 1 and 2). Both patients had a his-
tory of Lyme disease (LD) and associated tickborne co-infections. Patient 
1 had a history of persistent LD symptoms with a history of co-infections 
(anaplasma, babesia) with positive autoimmune markers after a short 
course of treatment in prior years, consistent with an underlying chronic 
inflammatory response. The second patient had a history of LD and 
Bartonella henselae, with prior exposure to Rickettsia rickettsii, and Rick-
ettsia typhi when she began treatment. Neither patient needed to be 
excluded from the prescribed combination therapy based on their 
medical history, as there was no allergy or intolerance to any medication 
or supplement, and no history of significant cardiac arrhythmias and/or 
QT prolongation on an electrocardiogram. 
2.2. Case studies 
Case history 1: The patient is a 53-year-old white male with a past 
medical history (PMH) significant for Lyme disease (positive IgM 
Western blot), anaplasmosis, babesiosis, prior exposure to Epstein-Barr 
virus, human herpesvirus 6 and cytomegalovirus, with a history of in-
testinal parasites. Exposure risk for tick-borne infections included 
frequent travel to highly Lyme endemic areas on Long Island. PMH also 
included frequently elevated mercury levels in the blood, hypothyroid-
ism, hypoglycemia, adrenal fatigue, low testosterone, low vitamin D, 
irritable bowel syndrome, and chronic insomnia. Significant autoim-
mune/inflammatory markers included a history of positive antinuclear 
antibodies (ANA) ranging between 1:40 and 1:320, positive rheumatoid 
factors (103, normal range less than 6) with a negative cyclic citrulli-
nated peptide, and positive IgG anticardiolipin antibodies. All other 
autoimmune markers were negative including negative single-stranded 
DNA, double-stranded DNA, Sjogren’s and Smith antibodies. After 
several months of treatment with antibiotics during the time period of 
2011–2012, the patient remained in relatively good health. He was 
never completely symptom free from his tick-borne infections but was 
able to work at a high intensity job in the financial industry and did not 
require follow-up with our medical practice until 8 years later. Western 
blots showed old exposure to Borrelia burgdorferi with evidence of 
several Lyme specific bands. 
He was seen again in January 2020 when his old Lyme symptoms 
began to relapse with moderate fatigue, insomnia (only sleeping 6 hours 
per night), occasional migratory pain in the muscles and joints, 
including low back, shoulders, ankles and feet, along with mild tremors 
and mild cognitive dysfunction. The patient stated that he was feeling 
approximately 85% of his normal functioning and repeat labs were 
performed. His Lyme C6 ELISA was negative, IgM and IgG immunoblot 
were negative with a negative PCR for Borrelia burgdorferi, along with 
negative Babesia testing and negative testing for other tickborne co- 
infections. Rheumatoid factor (IgM) was initially elevated at 154, ANA 
was positive at 1:320 (reference range less than 1:40) with a normal 
high-sensitivity CRP and normal ferritin level. All other autoimmune 
markers were negative. Mercury level in the blood was elevated at 15.3 
(normal range less than 10 μg/L), and Lead level was 1 in the blood 
(normal range 0–4 μg/dL). A complete blood count and comprehensive 
metabolic profile were within normal limits, as were immunoglobulin 
levels (IGA, IgM and IgG) and mineral levels (iodine, zinc, copper, 
magnesium). Hormone precursors were low, with low levels of preg-
nenolone (15, normal range 22–237 ng/DL), low levels of unconjugated 
Dehydroepiandrosterone (DHEA) (87, normal range 147–1760 ng/ 
deciliter), low total testosterone levels (232, reference range 250–1100 
ng/deciliter) and a low normal level of cortisol in the blood (8.4 μg/ 
deciliter, range between 4 and 22). 
On 3/20/2020, the patient called the emergency line of our medical 
office with symptoms that included anosmia, dysgeusia with a metallic 
taste, low-grade fevers (99.5–100.5 Fahrenheit), sweats (day and night 
occasionally interfering with sleep), body aches with flulike symptoms, 
low back pain, a dry cough with labored breathing, scratchy throat, 
severe headache, brain fog and diarrhea. Symptoms started one week 
prior and when testing returned positive for COVID-19, he had a 
computerized tomography (CT) scan in the emergency room showing a 
left lower lobe pneumonia. We started him immediately on hydroxy-
chloroquine as a loading dose of 400 mg BID  2 days, followed by 200 
mg TID  8 days, nitazoxanide 500 mg PO BID, and Zithromax 250 mg 
BID  10 days. He had also been using an albuterol inhaler that he 
received from the hospital emergency room several days prior, 2 pumps 
4  per day, without significant benefit in relieving his respiratory 
symptoms, along with acetaminophen 500 mg Q 4 hours. He was 
instructed to begin the above antibiotic regimen, along with immune 
and nutritional support (NS). This included several different probiotics, 
including acidophilus, lactobacillus, bifidobacterium and Saccharomyces 
boulardii, along with zinc 40 mg per day, Vitamin C up to 2 g, 3  per 
day, 3, 6 beta glucan 1000 mg per day, curcumin 1 g twice a day, sul-
foraphane glucosinolate 100 mg twice a day, NAC 600 mg twice a day, 
alpha lipoic acid 600 mg twice a day, and glutathione 2, 500 mg capsules 
twice a day, to be increased to 2 g taken all at once prn for acute res-
piratory distress. He was also instructed to alkalize his body with sodium 
bicarbonate and/or fresh squeezed lemons and limes as needed while 
using glutathione, and to order a pulse oximetry at home to measure his 
oxygen saturation. 
Day 11 postexposure, 4 days into the antibiotic regimen (day 4 of 
nitazoxanide) the patient began to clinically improve, although he still 
complained of anosmia, dysgeusia, poor appetite, a cough, significant 
shortness of breath, debilitating fatigue and several episodes of diarrhea 
per day with dehydration. Pulse oximetry’s remained at 95% or higher. 
A trial of 2 g of oral glutathione was tried for the moderate shortness of 
breath, which significantly improved his dyspnea within 1 h. A home 
nursing service was subsequently hired to administer IV fluids, as the 
patient became increasingly dehydrated secondary to significant night 
sweats and diarrhea with difficulty keeping down fluids. Two grams of 
IV glutathione was subsequently administered with 1 L of 0.9% normal 
saline, along with PO Pedialyte for electrolyte replacement. Oxygen via 
nasal cannula, up to 3 L per minute for several hours per day was used 
PRN for dyspnea. Pulse oximetry increased from 94 to 95%–98% while 
on a nasal cannula with some relief of symptoms. IV fluids with 2 g of 
glutathione administered over 1 h improved his sense of well-being and 
quickly improved his dyspnea each time it was administered daily. 
By day 17 (day 24 post exposure), his cough had resolved with no 
further dyspnea and body aches and headaches were also significantly 
improved. The only symptom that occasionally returned were night 
sweats with “air hunger” and a very mild, lingering cough which was 
intermittent. No other associated prior symptoms relapsed from COVID- 
19. After a detailed discussion, the patient reported that the present 
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symptoms were more suggestive of a reactivation of babesiosis he had 
experienced years prior. Since there were no associated fevers, wors-
ening cough, or significant dyspnea, and laboratory testing was pres-
ently unavailable, the patient was placed atovaquone/proguanil 100/ 
250 mg 4 tablets QD  3 days, followed by 2 PO BID, along with oral 
glutathione at a dose of 2 g up to twice a day PRN for shortness of breath. 
The patient continued to improve on this protocol. 
Case history 2: The patient is a 48-year-old, G4P4 female with a 15 
pack-year smoking history; a history of three consecutive C-sections; 
psoriasis; and a history of Lyme disease and associated tick-borne in-
fections (Bartonella henselae, Rickettsia rickettsii, Rickettsia typhi) which 
were diagnosed November 2016. Over the past three years, she received 
treatment for her tick-borne illness, and had a dramatic improvement. 
She had been symptom-free and off treatment for the past year, and prior 
to falling ill with COVID-19, the patient was healthy and eating a 
balanced diet with no notable health complaints. 
On Sunday, March 22, 2020, the patient woke up with 103F, severe 
dyspnea at rest that worsened with exertion, dry cough, chest tightness, 
nausea, dizziness, diarrhea, severe fatigue, body pains, weakness, 
shallow breathing, and anosmia. The patient was taken to the emer-
gency room, where they performed a chest x-ray which showed “hazy 
opacities and peribronchial thickening in the left mid and lower lung 
field concerning for pneumonia, possible atypical”. The patient was not 
tested for COVID-19 in the ER at the time of the X-ray due to the un-
availability of testing in NYC. She was given a loading dose of 500 mg of 
azithromycin in the emergency room and discharged with a diagnosis of 
“Suspected 2019 Novel Coronavirus Infection and Atypical Pneumonia”. 
On Monday, March 23, 2020, the patient was started on a combi-
nation therapy of azithromycin 250 mg PO q12h, and a loading dose of 
hydroxychloroquine 400 mg PO q12h, followed by maintenance doses of 
hydroxychloroquine 200 mg TID  9 days. Two days later, amoxicillin/ 
clavulanate 875-125 mg PO q12h was added for extended coverage of 
the pneumonia as her dyspnea persisted. During antibiotic therapy from 
March 23rd to March 30th, the patient experienced gradual improve-
ment but still complained of lingering symptoms of diarrhea and res-
piratory symptoms including a cough, dyspnea at rest that worsened 
with exertion, shallow breathing, inability to take a deep breath, and 
chest tightness. 
On March 31, reduced, liposomal glutathione was added to her 
antibiotic regimen along with 50 mg of zinc and 1-g TID of Vitamin C. 
The patient was given 2000 mg of L-glutathione PO all at once with 2 
Alka seltzer gold, along with alpha lipoic acid 600 mg, and N-ace-
tylcysteine 1200 mg. The patient saw immediate improvement 
described as “being able to breath better and having more energy” 
within an hour of use. After administration of the glutathione, the cough 
resolved and she was able to sleep through the night for the first time 
since the onset of illness, despite having been on her antibiotic regimen 
for several days. She was also able to take a deep breath for the first time. 
The following morning after administration of 2000 mg of PO gluta-
thione for a second time, the patient was able to ambulate, perform 
activities of daily living, and shower without pre-syncopal episodes 
arising from dyspnea. This was the first time she could perform activities 
of daily living since the onset of her illness. The following day, addi-
tional doses of glutathione were given, one time at a lower dose of 500 
mg PO, which did not have the same therapeutic effects as the higher 
dose of 2000 mg of GSH. All doses of glutathione administered to the 
patient were liposomal doses; and were subsequently administered at 
2,000 mg PO due to superior efficacy. Since that time, 5 days after 
receiving initial doses of GSH, the patient remained well and symptom 
free. As antibody tests were not readily available in NYC at the time of 
presentation, the patient was only able to receive a PCR test for COVID- 
19 two weeks after initiation of symptoms when she was asymptomatic, 
which was PCR negative. 
3. Discussion 
Several key clinical symptoms suggested a high likelihood of expo-
sure to COVID-19 in our patients, including the constellation of early 
prodromal symptoms of anosmia, hyposmia, and dysgeusia, along with a 
fever, sore throat, cough and shortness of breath. Apart from neurode-
generative diseases, the three major causes of a loss of smell are trauma, 
rhinosinusitis/nasal polyps, and viral infections [48]. Olfactory and 
gustatory dysfunctions have now been reported as a clinical presenta-
tion of mild-to-moderate forms of the coronavirus disease (COVID-19) 
[49]. 
COVID-19 risk factors include those with immunosuppression and 
underlying infections [13,15]. Patients with active Lyme disease can be 
immunosuppressed with immunoglobulin and subclass deficiencies [50] 
as well as potentially having multiple sources of inflammation driving 
the inflammatory process [51]. This needs to be considered in the list of 
risk factors potentially complicating treatment outcomes. For example, 
patient one was also diagnosed with elevated levels of mercury before 
contracting COVID-19, known to increase free radical/oxidative stress 
[52]. Glutathione and alpha lipoic acid have both been shown to be 
important in mitigation of mercury toxicity and regulation of heavy 
metals [53]. He also had symptoms consistent with active Lyme disease 
with migratory pain and multiple positive inflammatory markers (pos-
itive ANA, rheumatoid factors). Migratory pain is one of the hallmark 
symptoms of an active infection with Borrelia burgdorferi once other 
differential diagnostic possibilities have been ruled out [54]. He was 
ruled out for rheumatoid arthritis with a negative cyclic citrullinated 
peptide, and lupus erythematosus with negative double-stranded DNA 
and Smith antibodies, another potential source of migratory pain [54]. 
Patients who suffer from Lyme disease and relapsing fever borreliosis 
oftentimes experience Herxheimer reactions once antibiotics are initi-
ated [55] which has been shown to be due to the pro-inflammatory 
cytokines TNF-α, IL-6, and IL-8 [56]. These are some of the same cyto-
kines expressed during viral infection with COVID-19 [24]. Glutathione 
and alkalizing the body to decrease acidic byproducts has been shown to 
be helpful in decreasing symptomatology in this population of patients 
[57]. Glutathione metabolism has also been discovered to be the most 
important target of B. burgdorferi infection, and this pathway is essential 
for cytokine production, likely through glutathionylation [58]. Gluta-
thione and GSH precursors (NAC) with antioxidants that help regenerate 
GSH (alpha lipoic acid) have been an effective mainstay of treating 
cytokine storms and Herxheimer reactions in our tick-borne population 
for decades [59,60]. Both patients took glutathione for the first time on 
day ten/eleven, during the peak stage of their illness. According to 
recent published research [61], patients without severe respiratory 
distress during the disease course have lung abnormalities on chest CT of 
greatest severity approximately 10 days after the initial onset of symp-
toms. Both patients therefore had significant benefit with high-dose oral 
glutathione relieving their dyspnea during the peak stage of their illness. 
Our patients were also given zinc, 40–50 mg per day, and Vitamin C 
1–2 g TID. Zinc is known to play a central role in the immune system, 
and zinc-deficient persons experience increased susceptibility to a va-
riety of pathogens [62]. Zinc is crucial for normal development and 
function of cells mediating nonspecific immunity such as neutrophils 
and natural killer cells [62] and after zinc supplementation, the inci-
dence of infections, generation of tumor necrosis factor alpha and 
oxidative stress markers has been shown to be significantly lower in the 
zinc-supplemented than in the placebo group. Zinc supplementation in 
healthy human subjects also reduced the concentrations of the oxidative 
stress–related byproducts in the plasma; inhibited the ex vivo induction 
of TNF-α and IL-1β mRNA in mononuclear cells (MNCs) [63]; and pro-
vided protection against TNF-α–induced nuclear factor–κβ activation in 
isolated mononuclear cells [64]. Macrophages are adversely affected by 
zinc deficiency, which can dysregulate intracellular killing, and cytokine 
production [63]. 
We also used Vitamin C, another major free radical scavenger with 
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alpha lipoic acid and NAC. In the immune system, the major role of 
Vitamin C appears to be as an antioxidant, protecting host cells against 
oxidative stress caused by infections [65], especially infections affecting 
the lungs [65,66]. Other effects of Vitamin C include increased func-
tioning of phagocytes, proliferation of T-lymphocytes and production of 
interferon, while decreasing the replication of viruses [67]. Alpha lipoic 
was administered simultaneously with Vitamin C, which apart from 
being an antioxidant and inhibiting airway inflammation [41], increases 
GSH through release from oxidized glutathione, increasing GSH syn-
thesis, while activating the transcription factor Nrf2, and lowering 
expression of NF-kappa B [68]. Finally, NAC, a precursor of glutathione, 
was given at PO doses ranging from 1200 to 2400 mg/day, as it has been 
shown to lower the inflammatory response in patients with community 
acquired pneumonia in a randomized controlled trial [69] while 
increasing intracellular GSH and improving acute respiratory distress 
syndrome [70]. 
Glutathione is abundant in most cells, but is the most abundant 
antioxidant in the airway epithelial lining fluid, and acts as a vital intra- 
and extracellular antioxidant protecting against oxidative stress, helping 
to decrease pro-inflammatory processes in the lungs [71]. It has a rapid 
turnover and is quickly replenished by: (1) de novo synthesis by 
sequential action of two enzymes. The first, GCS (gamma-gluta-
myl-cysteine synthesase (ligase) is rate limiting and normally functions 
at substantially less than its maximum capacity because of feedback 
inhibition by GSH, while responding rapidly to GSH requirements [47]. 
In addition, GSH synthesis increases dramatically with oxidative stress 
through increase GCS transcription via Nrf2, providing there is adequate 
availability of cysteine, the rate limiting substrate [70]. Our patients 
took two Nrf2 activators, curcurmin and sulforaphane glucosinolate. 
Nrf2 suppresses macrophage inflammatory response by blocking 
proinflammatory cytokine transcription [72], and both curcumin and 
sulforaphane are potent Nrf2 activators that have been shown to 
decrease a broad range of inflammatory cytokines including IL-6 [73], 
helping to lower inflammation [74,75]. 
Elderly patients have been shown to have an increased risk from 
exposure to COVID-19 [13]. GCS activity decreases with age and from 
reduced recycling of reduced GSH from GSSG. With an adequate supply 
of cysteine, cells can have a large reserve capacity to increase GSH 
production and counter oxidative stress [47]. It is therefore possible that 
by administering large doses of NAC and glutathione, along with zinc, 
Vitamin C and Nrf2 activators, we lowered oxidative stress and in-
flammatory cytokine production, resulting in a rapid improvement in 
dyspnea and clinical symptomatology. A limitation of our study, apart 
from the small sample size however, is that we were unable to do lab-
oratory testing in our patients, including checking oxidative stress 
markers (lipid peroxides) as well as inflammatory markers (CRP, 
ferritin, D-dimer) and LDH which might demonstrate a change post GSH 
administration [76–78]. A randomized, controlled trial of GSH, gluta-
thione precursors with inflammatory/oxidative stress markers should be 
done in the future to fully elucidate the effects of blocking NF-kappaB, 
and to determine the effect of GSH and antioxidants on the clinical 
course of COVID-19 pneumonia and ARDS. 
4. Conclusion 
Activation of nuclear factor-kappaB (NF-kappaB) has been shown to 
be required for transcription of the genes for many of the pro- 
inflammatory mediators associated with ARDS. An intact inflamma-
tory response, in which NF-κB plays a major role, is also required for 
appropriate host defense against viruses [79] and in the later stages of 
bacterial pneumonia [80]. In preclinical models of sepsis and acute lung 
injury, associated with rapid and large increases in pro-inflammatory 
cytokines and other mediators, suppression of NF-κB activation has 
been shown to result in improved survival [81,82]. NAC, alpha-lipoic 
acid and GSH all inhibit TNF-α-induced NF-kappaB activation. Oral 
and IV glutathione as well as glutathione precursors (N-acetyl-cysteine, 
alpha-lipoic acid) may, therefore, represent a novel treatment approach 
for blocking NFKappaB and addressing “cytokine storm syndrome” and 
respiratory distress in patients suffering with COVID 19 pneumonia. 
Zinc, vitamin C and NRF 2 activators may also be helpful in decreasing 
the inflammatory response and lowering cytokine production. Ran-
domized controlled trials should be performed to evaluate the efficacy of 
these novel therapies in the treatment of patients with COVID-19 
pneumonia and ARDS. 
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